Investment
Features
FeesSafety
Academy
More
Pluang+

F.N.B. Corporation to release Q3 2026 earnings on Oct 19 with a follow-up conference call.

Company Fundamentals
29 Sep 2026
PRNewsWire
View Source
Neutral
F.N.B. Corporation to release Q3 2026 earnings on Oct 19 with a follow-up conference call.

F.N.B. Corporation announced it will publish its financial results for the third quarter of 2026 after market close on October 19, 2026. The company's top executives will hold a conference call on October 20 to discuss the results, with a live webcast available for investors. F.N.B. Corporation operates in seven states and D.C., offering a wide range of banking and wealth management services. This earnings release will provide insights into the company's performance and outlook in a competitive regional banking market.

F.N.B. Corporation's upcoming Q3 2026 earnings report is noted here with Pluang's Financials-sector snapshot as of Sep 29, 2026 23:52 WIB: Among 85 priced US Financial stocks, 17 rose and 67 fell. Notable movers include FLG (Flagstar Bank NA) at USD 11.84 with a -1.66% change and a typical hold time of 20 days, LMND (Lemonade Inc) at USD 44.60 with a +1.57% change and 100% buy order activity, and MTB (M&T Bank Corporation) at USD 217.03 with a -1.55% change and a typical hold time of 99 days. The most notable figure is LMND's 100% buy order activity on Pluang.

More News

Micron projects record $51.33B revenue driven by AI memory demand, with EPS soaring to $31.72 this quarter.

Micron projects record $51.33B revenue driven by AI memory demand, with EPS soaring to $31.72 this quarter.

Micron Technology is set to report record quarterly revenue of up to $51.33 billion, fueled by strong demand for high-bandwidth memory in the AI market. Earnings per share are expected to jump significantly to around $31.72, compared to $3.03 last ye...

Company Fundamentals
Bullish
22 minutes ago
Sangoma beats EPS estimates but misses revenue; acquisition deal boosts shares 35%.

Sangoma beats EPS estimates but misses revenue; acquisition deal boosts shares 35%.

Sangoma Technologies reported a smaller-than-expected loss with an EPS of -$0.08, beating analyst estimates of -$2.19, though its revenue of $48.55 million slightly missed expectations. Despite ongoing profitability challenges reflected in a negative...

Company Fundamentals
Bullish
2 hours ago
Iovance Biotherapeutics raises 2026 revenue forecast with strong Q2 sales and analyst optimism.

Iovance Biotherapeutics raises 2026 revenue forecast with strong Q2 sales and analyst optimism.

Iovance Biotherapeutics has increased its full-year 2026 revenue guidance to $410-$420 million, reflecting nearly 60% growth driven by strong U.S. demand for its cancer therapy Amtagvi, which generated $91 million in Q2 sales. Analyst Joseph Pantgini...

Analyst Insights
Bullish
3 hours ago
uniQure shares drop 37% after mixed results in Huntington's gene therapy trial

uniQure shares drop 37% after mixed results in Huntington's gene therapy trial

uniQure's stock fell sharply by 37% following a four-year update on its AMT-130 gene therapy for Huntington's disease, which showed reduced effectiveness from 80% at three years to 44% at four years, failing to reach statistical significance. Despite...

Market News
Bearish
3 hours ago
Gold faces pressure from rising yields and a strong dollar, with ETF demand its main support.

Gold faces pressure from rising yields and a strong dollar, with ETF demand its main support.

Gold prices are under significant pressure due to a break below $4,230, rising U.S. Treasury yields, and a stronger dollar, which have triggered renewed selling. Despite these headwinds, gold ETF holdings continue to recover, suggesting some investor...

Market News
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App